Human KidneyMAP® v 1.0
The Myriad RBM KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.
|1. Alpha-1-Microglobulin||2. Beta-2-Microglobulin|
|3. Calbindin||4. Clusterin|
|5. Cystatin-C||6. Glutathione S-Transferase alpha|
|7. Kidney Injury Molecule-1||8. Neutrophil Gelatinase-Associated Lipocalin|
|9. Osteopontin||10. Tamm-Horsfall Urinary Glycoprotein|
|11. Tissue Inhibitor of Metalloproteinases 1||12. Trefoil Factor 3|
|13. Vascular Endothelial Growth Factor|
Please Note: Creatinine and Microalbumin in urine samples only.
Intended for Research Use Only.